Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP3 | P08254 | 8/20 | 0.49 |
| ▸ | MMP9 | P14780 | 4/20 | 0.42 |
| ▸ | MME | P08473 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ANPEP | P15144 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.35 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
| ▸ | MMP8 | P22894 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27325467 | 0.82 | MMP3 (0.44) | MMP3MMP9ALDH1A1MEN1LMNA | |
| SCHEMBL21153561 | 0.82 | MME (0.43) | MMP3MMP9MMEALDH1A1MEN1 | |
| SCHEMBL20021565 | 0.79 | ALDH1A1 (0.45) | MMP9MMEALDH1A1MEN1LMNA | |
| SCHEMBL29311779 | 0.73 | MME (0.37) | MMP3MME | |
| SCHEMBL7027957 | 0.73 | MME (0.41) | MMEALDH1A1MMP8 | |
| SCHEMBL12537181 | 0.71 | ALDH1A1 (0.67) | MMP9ALDH1A1MEN1LMNAKMT2A | |
| SCHEMBL18456748 | 0.70 | MMP3 (0.33) | MMP3ALDH1A1FOLH1MMP2 | |
| SCHEMBL16508503 | 0.70 | MME (0.44) | MMP9MMEALDH1A1MEN1LMNA | |
| SCHEMBL20756785 | 0.70 | MMP3 (0.51) | MMP3MMP9ALDH1A1MEN1LMNA | |
| SCHEMBL19371329 | 0.70 | MMP3 (0.33) | MMP3MMP9FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067640-A1 | PHENYL MALEIMIDE LINKER AGENTS | FIREFLY BIO, INC. | 2024-02-29 | — | — | US | disclosed |
| US-20190209702-A1 | STEROIDS AND ANTIBODY-CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190209702-A1 | STEROIDS AND ANTIBODY-CONJUGATES THEREOF | SERPINA6, NR3C1, NR3C2 | MMP3 2441/4885MMP9 4068/4885MME 1994/4885 |
| US-20240067640-A1 | PHENYL MALEIMIDE LINKER AGENTS | TPX2, H1-4, MAPT | MMP3 3026/4885MMP9 4214/4885MME 1004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.